180 Life Sciences Corp. (NASDAQ:ATNF) Short Interest Down 19.8% in June

180 Life Sciences Corp. (NASDAQ:ATNF) was the target of a significant decrease in short interest in June. As of June 15th, there was short interest totalling 35,600 shares, a decrease of 19.8% from the May 31st total of 44,400 shares. Currently, 6.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 139,900 shares, the days-to-cover ratio is currently 0.3 days.

180 Life Sciences Price Performance

ATNF stock opened at $1.65 on Monday. 180 Life Sciences has a one year low of $1.31 and a one year high of $22.61. The company’s 50 day moving average price is $1.74 and its two-hundred day moving average price is $2.82.

180 Life Sciences (NASDAQ:ATNF) last issued its earnings results on Wednesday, May 15th. The company reported ($1.68) EPS for the quarter.

Institutional Investors Weigh In On 180 Life Sciences

A hedge fund recently bought a new stake in 180 Life Sciences stock. Armistice Capital LLC purchased a new position in 180 Life Sciences Corp. (NASDAQ:ATNF) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 131,000 shares of the company’s stock, valued at approximately $80,000. Armistice Capital LLC owned 2.46% of 180 Life Sciences at the end of the most recent reporting period. 4.07% of the stock is currently owned by institutional investors.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.